Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP19 | O94966 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12761342 | 0.78 | MEN1 (0.58) | HDAC1KMT2AMEN1USP7PDE7A | |
| SCHEMBL2995791 | 0.77 | GAA (0.46) | KMT2AUSP7GAARXFP1SMN1; SMN2 | |
| SCHEMBL12862604 | 0.75 | MEN1 (0.54) | HDAC1KMT2AMEN1USP7PDE7A | |
| SCHEMBL3118173 | 0.73 | SMN1; SMN2 (0.69) | KMT2AMEN1GAARXFP1SMN1; SMN2 | |
| SCHEMBL3755622 | 0.73 | MEN1 (0.58) | HDAC1KMT2AMEN1USP7PDE7A | |
| SCHEMBL18601303 | 0.71 | MEN1 (0.47) | HDAC1KMT2AMEN1USP7PDE7A | |
| SCHEMBL10563362 | 0.70 | NFE2L2 (0.60) | — | |
| SCHEMBL10563371 | 0.70 | NFE2L2 (0.60) | — | |
| SCHEMBL10563356 | 0.70 | NFE2L2 (0.60) | — | |
| SCHEMBL13241728 | 0.70 | SMN1; SMN2 (0.69) | KMT2AMEN1GAARXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | SIGA TECHNOLOGIES, INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189685-A1 | Antiviral Drugs for Treatment or Prevention of Dengue Infection | EIF2AK2, HAVCR2, SNRPE | HDAC1 1078/4885KMT2A 3347/4885MEN1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.